• Citer

Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.

par Taieb, Julien;Tabernero, Josep;Mini, Enrico;Subtil, Fabien;Folprecht, Gunnar;Van Laethem, Jean-Luc ;Thaler, Josef;Bridgewater, John;Petersen, Lone Nørgård;Blons, Helene;Collette, Laurence;Van Cutsem, Eric;Rougier, Philippe;Salazar, Ramon;Bedenne, Laurent;Emile, Jean-François;Laurent-Puig, Pierre;Lepage, Come;PETACC-8 Study Investigators,
Référence Lancet oncology, 15, 8, page (862-873)
Publication Publié, 2014-07

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Résumé :

Since the 1990s, fluorouracil-based adjuvant chemotherapy has significantly reduced the risk of tumour recurrence in patients with stage III colon cancer. We aimed to assess whether the addition of cetuximab to standard adjuvant oxaliplatin, fluorouracil, and leucovorin chemotherapy (FOLFOX4) in patients with stage III colon cancer improved disease-free survival (DFS).